Holland & Barrett's decision to put SlimBiome on the shelves of more than 1,600 stores gives OptiBiotix Health PLC (LSE:OPTI) its most visible retail platform yet. The launch of the retailer's own-label FORMI Weight Loss Complex, announced on 2 September 2026, follows a year in which the microbiome specialist grew Revenue by a third, lifted gross margins to 53% and set a deadline of profitability across all Business units by the end of 2026.
The question is whether these wins, together with a first NHS clinical trial for WellBiome and the long-awaited demonstration of its SweetBiotix sugar substitute, can move a business that still lost £3.9m before tax in 2025 on revenue of £1.2m, and whose runway has depended partly on selling stakes in listed spin-outs.
Latest development: Holland & Barrett launches FORMI with SlimBiome
On 2 September 2026 OptiBiotix announced that Holland & Barrett has launched FORMI Weight Loss Complex, a raspberry-flavoured drink sachet containing SlimBiome, online and through more than 1,600 stores across 19 countries, including over 700 in the UK. It carries authorised health claims covering weight management, blood sugar and satiety.
The launch stems from a three-year non-exclusive Trademark licence signed in December 2025; financial terms were not disclosed.
OptiBiotix is positioning SlimBiome as a natural option for consumers who cannot tolerate GLP-1 weight-loss drugs or want support after stopping them, citing third-party estimates valuing the GLP-1 support supplement market at $1.8bn in 2025, rising to $8.9bn by 2034. Chief executive Stephen O'Hara said SlimBiome "is increasingly being recognised as a clinically validated, natural approach to appetite, hunger and satiety management."
The significance lies in the channel: a mainstream UK health retailer adopting the ingredient under its own Brand gives OptiBiotix consumer visibility its ingredient-supply model has struggled to generate.
Business overview: microbiome science sold as ingredients and brands
OptiBiotix develops compounds that modulate the human gut microbiome. Its first-generation products are prebiotic fibres: SlimBiome, aimed at hunger and food cravings, and WellBiome, a mineral-enriched fibre complex for gut health. Its second-generation platform, SweetBiotix, uses enzymes to convert natural sweeteners such as stevia, and even sucrose, into low-calorie prebiotic fibres intended as sugar substitutes.
Revenue comes from bulk ingredient sales to brand owners, trademark licensing, milestone payments from development partners and direct-to-consumer sales through Amazon and Chinese e-commerce. In 2025 SlimBiome was launched in Hydroxycut, described by the company as the leading US weight-loss brand.
Of FY2025 revenue of £1,166k, the US contributed 30%, the UK 27%, the rest of Asia 23%, India 14% and China 6%. OptiBiotix also holds stakes in two AIM-quoted spin-outs, ProBiotix Health and SkinBioTherapeutics.
FY2025 results: revenue up 34%, margins improve, but losses widen
Final results for the year ended 31 December 2025, published on 28 May 2026, showed revenue of £1,166k, up 34% from £870k. Gross Profit rose 85% to £614k as the gross Margin improved to 53% from 38%.
Losses nonetheless widened. The operating loss increased to £3,132k from £2,266k, with administrative expenses of £3,746k including £1,061k of share-based payments. The loss before tax was £3,943k against £1,866k, the gap reflecting a £417k share of losses at associate ProBiotix Health and a £402k fair-value loss on investments. Basic loss per share was 3.84p compared with 1.84p.
Year-end cash was £1,037k, up from £739k, with no borrowings. Holdings in ProBiotix and SkinBioTherapeutics were valued at £6.45m in aggregate at the year end, although the SkinBioTherapeutics stake was subsequently reduced to 2.2% through post-period sales of 8.9m shares for approximately £787k, which the board said extend the runway into the first half of 2027. No Dividend was paid. The audit report was unqualified and the directors concluded the group is a going concern, noting that "results to date in 2026 indicate that revenue is likely to come through as anticipated for the year."
What could drive the stock next?
Management has set a target of profitability across all business units by the end of 2026 (LSE:OPTI). The 1 April 2026 trading update outlined £500k to £600k of annualised cost savings, including a 78% reduction in Marketing spend in January and February, alongside a targeted 31% cut in SlimBiome production costs by the second quarter, progressing towards 48%. Half-year results, due in September on last year's timing, will show whether these savings are flowing through.
Order momentum is another marker. OptiBiotix reported more than £800k of orders from four partners before the end of January 2026, including a 24-tonne SlimBiome order from Meelung Trading in Taiwan, delivered in quarterly tranches through 2026.
SweetBiotix is the longer-dated prize. A single-enzyme process announced in November 2025 delivered yields of around 90% at lower cost, and the company held its first investor sampling event on 24 June 2026, describing it as successful. A Manufacturing or licensing agreement with a sugar or ingredients group would be material for a company of this size; regulatory pathways have not yet been detailed.
On the clinical side, a double-blind, placebo-controlled trial of WellBiome in up to 60 cardiac surgery patients at Hull University Teaching Hospitals NHS Trust, announced on 24 February 2026, will measure hospital stay lengths and complication rates. Mr O'Hara said that "if successful it could lead to WellBiome becoming the standard of care for NHS patients undergoing surgery." No readout date has been given.
Risks investors should watch
Scale is the central issue. Annual revenue of £1.2m does not yet cover a cost base of more than £3.7m, and the profitability target depends on both cost cuts and order conversion. Cash of just over £1m at the end of 2025 has been supplemented by SkinBioTherapeutics share sales; the remaining portfolio is exposed to volatile small-cap AIM prices, as the £402k fair-value loss in 2025 showed. Further asset sales or an Equity raise, following the May 2025 placing, cannot be ruled out if trading falls short.
Customer concentration is high, with four partners accounting for the January order book, and the Holland & Barrett licence is non-exclusive. Share-based payments of £1,061k in 2025 signal continued dilution. SweetBiotix has already suffered delays linked to partner scale-up difficulties, and the WellBiome trial is small and may not produce a decisive result.
Outlook
OptiBiotix enters the final third of 2026 with its strongest commercial narrative in years: a mainstream UK retail launch, a record start-of-year order book, rising margins and a defined cost-reduction plan. Against that, the audited numbers still show a business burning cash and leaning on Investment holdings to bridge the gap. The half-year report should reveal whether savings are being delivered, how much of the order book has converted to revenue and what runway remains. Beyond that, a first SweetBiotix commercial agreement or a positive WellBiome trial outcome would be the catalysts most capable of changing the scale of the story.






Please wait processing your request...